Survivin expression may affect the neoadjuvant chemotherapy response in breast cancer patients

To investigate whether there is a predictive effect of NF-kappaB, survivin, and Ki-67 expressions on pathological response and disease relapse in breast cancer (BC) patients. Ki-67, survivin and NF-kappaB expressions were analyzed in the pathology specimens of breast biopsy before and after neoadjuvant chemotherapy (NeoCT) in BC patients (n=52). Event -free survival (EFS) (defined as recurrence or metastasis free) analyze was performed. The median overall survival was 43.5 months and the median EFS was 51 months (95% CI: 33.3-68.9) in all patients. The expression percentages of NF-kappaB, survivin, and Ki-67 significantly decreased after NeoCT (p<0.001). Survivin expression level before NeoCT was significantly higher in patients who did not respond to NeoCT than both partial-responders and complete-responders (p=0.038, p=0.010, respectively). Type of NeoCT was the only independent factor on pathological response status (p=0.007). Addition of taxanes to NeoCT improved pathological complete response rates about six times. However, no predictor was found to be a prognostic factor for EFS in multivariate analyze. Higher survivin expression level before NeoCT may be associated with poor pathological response to NeoCT. These findings must be tested with prospective clinical trials.


1. Hidalgo JV, Bronsert P, Orlowska-Volk M, et al. Histological Analysis of ?? T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. Front Immunol 2014; 5: 632.

2. Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol 2013; 717: 58-66.

3. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-888.

4. Rundall BK, Denlinger CE, Jones DR. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004; 136: 416-425.

5. Gionet N, Jansson D, Mader S, Pratt MA. NFkappaB and estrogen receptor alpha interactions: Differential function in estrogen receptornegative and -positive hormone-independent breast cancer cells. J Cell Biochem 2009; 107: 448-459.

6. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997; 272: 14914-14920.

7. Montagut C, Tusquets I, Ferrer B, et al. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006; 13: 607-616.

8. Jones RL, Rojo F, A'Hern R, et al. Nuclear NF?B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol 2011; 64: 130-135.

9. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.

10. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006; 244: 164-171.

11. Singh M, Bleile MJ, Shroyer AL, Heinz D, Jarboe EA, Shroyer KR. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl Immunohistochem Mol Morphol 2004; 12: 296-304.

12. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562-4574.

13. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large populationbased cohort of a cancer registry. Breast Cancer Res Treat 2013; 139: 539-552.

14. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205-211.

15. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116: 53-68.

16. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval [Internet]. Available from: complianceregulatoryinformation/guidances/ucm 305501

17. Chávez-MacGregor M, González-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol 2010; 12: 461- 467.

18. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 2007; 97: 659-669.

19. Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005; 92: 147-155.

20. Yin HF, Wang YH, Qin XQ, et al. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer]. [Article in Chinese]Zhonghua Zhong Liu Za Zhi 2009; 31: 858-862.

21. Lee J, Im YH, Lee SH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 2008; 61: 569-577.

22. Buchholz TA, Garg AK, Chakravarti N, et al. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 2005; 11: 8398-8402.

23. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.

24. Yamashita S, Masuda Y, Kurizaki T, et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 2007; 27: 2803-2808.